source
- Commenters urge FDA to allow flexible trial designs for rare diseases, questioning RCT emphasisStakeholders who submitted comments to the FDA’s public docket on statistical methods for rare disease studies emphasized the need for greater flexibility in how trials are designed and what types…
- Big pharma say they will stop opening new trial sites in Xinjiang and Chinese military hospitalsSeveral of the world’s largest pharmaceutical companies told a U.S. House Select Committee on China that they will not start new clinical trial sites in the Xinjiang region of China or at hospitals…